NASDAQ:CELU Celularity Q1 2025 Earnings Report $0.77 -0.11 (-12.49%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$0.80 +0.03 (+3.38%) As of 08:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Celularity EPS ResultsActual EPS-$1.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACelularity Revenue ResultsActual Revenue$5.74 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACelularity Announcement DetailsQuarterQ1 2025Date8/29/2025TimeAfter Market ClosesConference Call DateFriday, August 29, 2025Conference Call Time12:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Celularity Earnings HeadlinesNEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of DirectorsMay 6, 2026 | markets.businessinsider.comCelularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic TransformationMay 1, 2026 | globenewswire.comMillionaire warns: Move your money before May 15Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2025 - says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. When the Fed cut rates in 2020, his readers had a chance at 62% gains. A 2022 rate-hike signal produced 117% in under a month. Now Benedict has identified the single ticker he believes will be at the center of the coming money flows - and he's revealing it free before May 15.May 12 at 1:00 AM | Brownstone Research (Ad)Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenueApril 28, 2026 | bizjournals.comLanghorne’s Nexgel transforms near disaster into ‘three-team trade’ acquisitionApril 28, 2026 | msn.comNEXGEL Appoints Ian Blackman as Chief Financial OfficerApril 27, 2026 | globenewswire.comSee More Celularity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email. Email Address About CelularityCelularity (NASDAQ:CELU) is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens. The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells. Among its lead investigational candidates is a placental-derived NK cell therapy being evaluated in both oncology and immuno-infectious disease settings. Celularity also explores exosome-based approaches to deliver therapeutic proteins and RNA payloads to specific tissues. Founded by Dr. Robert L. Hariri—who previously established and led Celgene’s cellular therapeutic research efforts—Celularity went public in April 2021 via a special purpose acquisition company (SPAC) transaction and now trades on the Nasdaq under the symbol CELU. The company is headquartered in Florham Park, New Jersey, with research and manufacturing operations designed to support scalable production of its cell therapy candidates. Under the leadership of President and Chief Executive Officer Robert L. Hariri, M.D., Ph.D., Celularity brings together a team of experts in cell biology, process development and clinical research. The company maintains collaborations with academic centers and industry partners to advance its portfolio through clinical trials, with the goal of delivering novel, off-the-shelf therapies to patients worldwide.View Celularity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItMercadoLibre Boldly Invests in Growth: Discount DeepensManic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand NowTapestry Stock Drops After Strong Quarter and Raised OutlookMarketBeat Week in Review – 05/04 - 05/08Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
